NIH Department of Laboratory Medicine
Bethesda, Maryland, 20892, United States
NCT Number: NCT01707472
The primary objective of this study is to assess the safety and tolerability of simtuzumab (formerly GS-6624) in HIV and/or hepatitis C virus (HCV)-infected adults with evidence of liver fibrosis.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Bethesda, Maryland, 20892, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
700 mg intravenously for a total of 12 infusions.
Other names: Anti-LOXL2 Monoclonal Antibody, GS-6624
Time frame: First dose date up to Week 24 plus 30 days
Time frame: Baseline; Week 24
The Ishak fibrosis score measures the degree of liver fibrosis (scarring) and ranges from 0 (best) to 6 (worst). A negative value in change from baseline indicates an improvement and a positive value indicates worsening.
Time frame: Baseline; Week 24
Time frame: Baseline; Week 24
Time frame: Baseline; Week 24
Time frame: Baseline; Week 24
Gilead Sciences
Industry
A Phase 2a Study of an Anti-LOXL2 Monoclonal Antibody (GS-6624) in HIV and/or Hepatitis C- Infected Subjects With Liver Fibrosis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01231685
Blood-Borne Infections, Coinfection
Vancouver, British Columbia, Canada
View Trial DetailsNCT02060162
Africa, Alcohol Use Disorder
Lusaka, Zambia
View Trial DetailsNCT03908294
Blood-Borne Infections, Communicable Diseases
Frankfurt am Main, Germany
View Trial DetailsNCT01988753
Blood-Borne Infections, Communicable Diseases
Houston, Texas, United States
View Trial Details